9 results
Primary Efficacy Objectives• To compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving VS-6063 or placebo.• To compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving…
The main purpose of this study is to assess whether the study drug anetumab ravtansine is more effective than treatment with vinorelbine in patients with stage IV, mesothelin overexpressing malignant pleural mesothelioma. Efficacy will be measured…
This study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone treatment (study treatments) in patients with advanced idiopathic pulmonary fibrosis (IPF) and intermediate or high probability of Group 3…
This is a prospective, multi-center, randomized, two-arm, single-blind post market study designed to compare standard tissue closure techniques (control) to standard tissue closure techniques plus the PleuraSeal Sealant System (study device) for…
Primary objective:Investigate whether the use of a digital drainage system leads to a shorter hospital stay in patients with primary pneumothorax, in whom clinical drainage is indicated. Secondary objectives: To investigate whether the use of a…
The primary objective is to determine the efficacy (as measured by pulmonaryfunction) and safety of CNTO 888 in subjects with IPF. The major secondary objectives are to assess theeffect of CNTO 888 on measures of disease progression, to assess the…
Primary Objectives:• To compare progression free survival (PFS) as determined by blinded independent central review (BICR) and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first…
To demonstrate that removal of drains exclusively based on digital drainage system data is non-inferior to additional clamping trials regarding recurrent pneumothorax requiring chest tube reinsertion.
To investigate the feasibility of immediate P/D followed by cisplatin/pemetrexed chemotherapy (or carboplatin/pemetrexed chemotherapy) or deferred P/D after cisplatin/pemetrexed chemotherapy (or carboplatin/pemetrexed chemotherapy) in patients with…